×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Ovarian Cancer

Feature Video
Dr Shannon Westin, a clinical investigator at the MD Anderson Cancer Center, discusses PARP inhibition for patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
Beth Fand Incollingo
In her talk, Hennessy will also emphasize the importance of educating patients about their cancers and care options, and of the need for physicians to consider treatments that go beyond the standard of care, including targeted medicines and clinical trials.
Brielle Urciuoli
A drug that is used to treat leukemia may also have potential in treating an extremely rare kind of ovarian cancer called small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
KAREN J. RIBLER
Finding her way into a clinical trial took a lot of research for one patient with ovarian cancer. Now, she’s guiding others.
Katie Kosko
Rick Boulay, a gynecologic oncologist and classically trained singer, will host a performance to raise money for cancer charities.
Kristie L. Kahl
After a cancer diagnosis and treatment, one may question when they will actually start to feel “normal” again, whatever that may be. The Ovarian Cancer Prognosis and Lifestyle (OPAL) study set out to help women with ovarian cancer to understand just that.
Kristie L. Kahl
Should women who are not known to have a hereditary risk for ovarian cancer get screened? The US Preventive Services Task Force says no.
 
Brielle Urciuoli
PARP inhibitors have drastically changed the treatment landscape – and outcomes – of patients with ovarian cancer. However, despite promise shown among this class of drugs, it is still unclear which agent is the best to use in the maintenance setting.
Khevin Barnes
My wife died on Valentine's Day, and I never thought that the holiday would be the same again.
Kristinna Abalos
If your chair was cold, I knew you were two floors down in the NICU cradling your only child – the only one I’d be able to give you – making sure his IV and nutrition lines were also connected and beeping lively and skipping at the same beat as mine.
Brielle Urciuoli
Overall survival should not be the sole factor in determining whether a drug gets approved, according to Maurie Markman, M.D.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable